![Paolo Tarantino: The longest follow up to date of a metastatic trastuzumab trial.](https://oncodaily.com/pub/uploads/2023/06/Paolo-Tarantino-1-1280x1280.jpeg)
Photo from Paolo Tarantino/Twitter
Sep 21, 2023, 04:05
Paolo Tarantino: The longest follow up to date of a metastatic trastuzumab trial.
Paolo Tarantino, a clinical research fellow at the Dana-Farber Cancer Institute, shared the following insight on X/Twitter:
“The longest follow-up to date of a metastatic trastuzumab trial: after 20 years from receiving TCH, 10% of the patients included in this phase 2 study were still alive: click here.
How to recognize & increase the rate of long-term survivors? Click here.”
Source: Paolo Tarantino/Twitter
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023